Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jakub Rzeszotko"'
Autor:
Karolina Jendryczko, Jakub Rzeszotko, Mateusz Adam Krzyscik, Jakub Szymczyk, Jacek Otlewski, Anna Szlachcic
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Targeted therapies are a promising alternative to conventional chemotherapy, with an increasing number of therapeutics targeting specific molecular aberrancies in cancer cells. One of the emerging targets for directed cancer treatments is fibroblast
Externí odkaz:
https://doaj.org/article/916c9edb3c4d499ab88c5169dc5b691f
Autor:
Karolina Jendryczko, Jakub Rzeszotko, Mateusz Adam Krzyscik, Anna Kocyła, Jakub Szymczyk, Jacek Otlewski, Anna Szlachcic
Publikováno v:
Molecular pharmaceutics. 19(5)
With a wide range of available cytotoxic therapeutics, the main focus of current cancer research is to deliver them specifically to the cancer cells, minimizing toxicity against healthy tissues. Targeted therapy utilizes different carriers for cytoto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e19b478f35ea34aea11c2d6a7aafce
https://pubmed.ncbi.nlm.nih.gov/35389227
https://pubmed.ncbi.nlm.nih.gov/35389227
Autor:
Jacek Otlewski, Karolina Jendryczko, Anna Szlachcic, Mateusz Adam Krzyscik, Jakub Szymczyk, Jakub Rzeszotko
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Targeted therapies are a promising alternative to conventional chemotherapy, with an increasing number of therapeutics targeting specific molecular aberrancies in cancer cells. One of the emerging targets for directed cancer treatments is fibroblast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b60f7af4288584394b19e3f55751e0
http://europepmc.org/articles/PMC8636100
http://europepmc.org/articles/PMC8636100
Autor:
Antoni G Wiedlocha, Karolina Jendryczko, Jacek Otlewski, Julia Chudzian, Jakub Rzeszotko, Anna Szlachcic, Łukasz Opaliński, Natalia Skinder
Publikováno v:
Cancers
Cancers, 12(10):12102992. MDPI AG
Volume 12
Issue 10
Cancers, Vol 12, Iss 2992, p 2992 (2020)
Cancers, 12(10):12102992. MDPI AG
Volume 12
Issue 10
Cancers, Vol 12, Iss 2992, p 2992 (2020)
Fibroblast growth factor receptors (FGFRs) are emerging targets for directed cancer therapy. Presented here is a new FGFR1-targeting conjugate, the peptibodyF2, which employs peptibody, a fusion of peptide and the Fc fragment of human IgG as a select
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7ea811120f1adb2f5969131cfa5fe35
http://europepmc.org/articles/PMC7602595
http://europepmc.org/articles/PMC7602595